Share on

Global Renal Biomarkers Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Diagnostic Technique, Type & Region - Industry Forecasts (2023 to 2028)

Published: March, 2023
ID: 5219
Pages: 175
Formats: report pdf report excel report power bi report ppt

Renal Biomarkers Market Size (2023 to 2028):

According to our research report, the global renal biomarkers market size was valued at USD 1165.14 Million in 2023 and is expected to reach USD 1657.22 Million by 2028 and is forecasted to grow at a CAGR of 7.3% during the forecast period.

A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes pathogenic process responses to a therapeutic intervention. Renal biomarker consists of serum creatinine (SCR), blood urea nitrogen (BUN), urinary albumin/protein, and volume excretion.


Advancements in genetics, growing incidence of kidney and renal diseases primarily fuel the renal biomarkers market growth.

Acute kidney injury (AKI) and chronic kidney diseases (CKD) substantially increase morbidity and mortality. Some researchers are going into the laboratories to develop a procedure to diagnose acute kidney injury and chronic kidney diseases with surrogate marker GFR, such as serum creatinine (SCr). The growing demand for innovative techniques in the medical sector is driving the need of the market. The government organization is working towards the development in the field of renal biomarkers as there is a tremendous demand for the non-invasive biomarker process. Increasing scale research centers are also propelling the growth rate of the market. 

Additionally, Y-O-Y growth in the occurrence of cardiovascular diseases, chronic kidney diseases, and diabetes are significantly contributing to the development of the market. Increasing R & D activities and rising diagnostic applications of biomarkers are further anticipated to further flourish the renal biomarkers market. The Contract Research Organizations (CROs) are increasing in huge numbers, which is estimated to favor the market's growth rate. The development rate of chronic kidney diseases among children increases, which is anticipated to impel the market demand. In 2018, according to the European Renal Association- European Dialysis and Transplant Associations data, more than 850 million people were diagnosed with kidney disease. A vast number of patients affected with a different form of kidney diseases is rising, which is leading to the improvement of new renal biomarkers that are expected to bolster the market growth.


The current biomarkers are not specific and cannot work at a particular target as they cannot detect some of the diseases. There is no adequate or proper way to detect acute and chronic kidney diseases, which is estimated to hinder the renal biomarkers market growth. 

Furthermore, an inappropriate way to identify acute and chronic kidney diseases is one major factor in limiting the market growth. Inadequate reimbursement policies impede market demand. Usage of irregular and imperfect standard quality is predicted to hinder the renal biomarkers market growth in Europe. Hurdles associated with regulatory bodies are likely to restrict the market. The vast amount required for drug discovery, development, and establishment is obstructing the market growth.

Impact of COVID-19 on the global renal biomarkers market:

The novel coronavirus (COVID-19) is a transmitted disease that is caused by the SARS-CoV-2 reagent. The coronavirus has affected all parts of the body like cardiovascular, gastrointestinal, and other organ diseases. The patients with COVID-19 symptoms having kidney diseases, and their involvement are widespread. The sudden outburst of COVID-19 has got considerable effects on the occurrence and management of kidney diseases. The high incidences of diabetes and blood pressure are the primary cause of kidney-related diseases. COVID-19-associated acute kidney injuries are concerned with death rates and serve as independent risk factors for all-cause in-hospital death in patients with COVID-19. The advancements of regional increase in COVID-19 cases limit hospital resources. Because of the quick advancements in genomic technologies, genetics analysis has become essential in clinical practice and research. Renal biomarkers are integrated with genetic-level technological developments to detect, diagnose, and treat kidney diseases—the occurrences of kidney injuries or damages and their association with the urinary biomarkers in hospitalized COVID-19 patients.




Market Size Available

2022 to 2028

Base Year


Forecast Period

2023 to 2028

Segments Covered

By Diagnostic Technique, Type, End-User, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Covered

North America, Europe, Asia Pacific, Latin America, Middle East & Africa

This market research report on the global renal biomarkers market has been segmented based on the diagnostic technique, type, end-user, and region.

Renal Biomarkers Market - By Diagnostic Technique:

  • Chemiluminescent Enzyme Immunoassay

  • Colourimetric Assay               

  • Enzyme-Linked Immunosorbent Assay       

  • Liquid Chromatography-Mass Spectrometry            

  • Particle-Enhanced Turbidimetric Immunoassay      

Based on diagnostics techniques, the enzyme-linked with immunosorbent assay is considered to hold the largest share of the renal biomarkers market, accounting for 44.3% of the claim in terms of values. Increasing demand to promote quality healthcare services is propelling the growth rate of the market.

Renal Biomarkers Market - By Type:

  • Up-Regulated Proteins  

  • Interleukin 18

  • Kidney injury molecule 1

  • Neutrophil gelatinase-associated lipocalin

  • Functional Biomarker         

  • Serum Creatinine

  • Serum Cystatin C

  • Urine Albumin

Based on the type, the functional biomarker segment is expected to hold the largest share of the market during the period and is observed to have a CAGR value of 6.94% or renal biomarkers. Increasing chronic kidney diseases and creating awareness of serum creatinine biomarkers by private and public sectors elevate the market demand.  

Renal Biomarkers Market - By End User:

  • Diagnostic Labs      

  • Hospitals  

  • Outpatient Clinics 

  • Research Centres 

Based on the renal biomarkers market, the diagnostic labs are considered to have the largest market share. Diagnostic labs account for 34.9% in terms of value over the forecast period. The Outpatient clinic's segment is expected to register a CAGR value of a 7.2% share of renal biomarkers growth. The growing economy in both developed and developing countries is boosting up the growth rate of the market.

Renal Biomarkers Market - By Region:

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • The Middle East and Africa

Regionally, the North American region occupied most of the shares in the global renal biomarkers market in 2019. The area has contributed 32% of the U.S. share owing to the escalating expenditure on healthcare, strong economic growth, and receiving novel diagnostic methods. The U.S. holds the highest shares of the market and is continuing the same growth rate during the period.

The European market is expected to showcase promising growth for the growth of renal biomarkers during the analysis period. The increase in this region is expected to have a share of 21.1% over the market. The factors responsible for the growth are adopting the latest technology in the healthcare sector and the high expenditure capacity of the population. The UK is accounted to hold the top position with the largest share in the market. Quick launch and inventions of the products to improve healthcare services and infrastructure are escalating the market demand. Notable growth in the elder people population leading to the increase of disease ailments expands the market portfolio. Germany, France, Italy, Spain, and the rest of Europe are projected to have considerable growth in the renal biomarkers market. Rapid advancements in genetics, which leads to the enhancement of upgraded renal biomarkers in treating patients with kidney disorders, are thriving the market growth.

The Asia-Pacific market is expected to have the fastest growth rate over the analysis period. Soaring occurrences of renal diseases, growing older people population, and inadequate reimbursement policies are likely to hamper the growth of the renal biomarkers market. Countries like India and China are considered to provide a high range of opportunities for the renal biomarkers market.

The Latin American market is expected to have a steady growth over the period owing to the adoption of advanced technology. Growing occurrences of diseases like high blood pressure and diabetes are some factors propelling the market's demand. Brazil is deemed to have enormous market opportunities with increasing support from private and public healthcare expenditure.

The Middle East & Africa region has a steady growth rate. The growing geriatric population, increasing diabetic population, rising awareness of acute and chronic kidney diseases, and increasing diagnostics and therapeutics procedures are significant factors for growth in this region. In this region, the South Africa market is soaring due to strong growth in healthcare and reimbursement programs from the government in developing countries.


Noteworthy companies playing a leading role in the global renal biomarkers market profiled in the report are Abbott Diagnostics, F. Hoffmann-La Roche AG, Beckman Coulter Inc., Astute Medical Inc., Siemens Healthcare Diagnostics Inc., Thermo Fisher Scientific Inc., Alere Inc., bioMérieux SA, and Randox Laboratories Ltd.


  • On May 13, 2020, Corvus Pharmaceuticals Inc., a pharmaceutical company, has focused on developing and commercializing precisely targeted oncology therapies for renal cell cancer. 

  • On February 21, 2020, researchers introduced a biomarker for early detection of deduction of diabetic kidney failure at the National Institute of Mental Health and Neurosciences (NIMHANS), Bangalore. The name of a biomarker is Microalbuminuria (MIA).

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample